Founder-chairperson Kiran Mazumdar-Shaw believes the company's biggest acquisition will be a game changer for Biocon over the next decade
According to Kiran Mazumdar-Shaw, Viatris’s biosimilars revenues are estimated to be in excess of $1 billion next year.